ASKG315 / Aosaikang Pharma - LARVOL DELTA

A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: AskGene Pharma, Inc. | Initiation date: Sep 2022 ➔ Aug 2023

Combination therapy • Metastases • Trial initiation date • Oncology • Solid Tumor

A Study of ASKG315 in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: AskGene Pharma, Inc. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Oct 2023 ➔ Dec 2023

Enrollment open • Metastases • Trial primary completion date • Oncology • Solid Tumor

"#AskGene Presents Latest Results on #ASKG315 and #ASKG915 at #SITC22 https://t.co/srKNP2Y4tE" (@1stOncology)

Oncology

ASKG315 - An IL-15 Prodrug with Antibody-Like PK, Enhanced Safety and Expanded Therapeutic Window (SITC 2022) - "A first-in-human (FIH) study for ASKG315 is expected to start in the second half of 2022. Ethics Approval The uses of the animals in the in vivo studies were approved by the ethics committees of the CROs who performed the studies."

Clinical • Oncology • CD4 • CD8 • IL15

A Study of ASKG315 in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=56 | Not yet recruiting | Sponsor: AskGene Pharma, Inc.

New P1 trial • Oncology • Solid Tumor

A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: AskGene Pharma, Inc.

Combination therapy • New P1 trial • Oncology • Solid Tumor